In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3-CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16-75) years. AML was de novo in 58%, therapy-related (t-AML) in 37% and secondary after myelodysplastic syndrome (s-AML) in 5%. Cytogenetics revealed a complex karyotype in 43%. Besides MYST3-CREBBP, whole-genome sequencing on a subset of 10 patients revealed recurrent mutations in ASXL1, BRD3, FLT3, MLH1, POLG, TP53, SAMD4B (n = 3, each), EYS, KRTAP9-1 SPTBN5 (n = 4, each), RUNX1 and TET2 (n = 2, each). Complete remission after intensive chemotherapy was achieved in 84%. Median follow-up was 5·48 years; five-year survival rate was 17%. Patients with s-/t-AML (P = 0·01) and those with complex karyotype (P = 0·04) had an inferior prognosis. Allogeneic haematopoietic cell transplantation (allo-HCT) was performed in 21 (36%) patients, including 15 in first complete remission (CR1). Allo-HCT in CR1 significantly improved survival (P = 0·04); multivariable analysis revealed that allo-HCT in CR1 was effective in de novo AML but not in patients with s-AML/t-AML and less in patients exhibiting a complex karyotype. In summary, outcomes of patients with t(8;16) are dismal with chemotherapy, and may be substantially improved with allo-HCT performed in CR1.
- Klíčová slova
 - acute myeloid leukaemia, allogeneic haematopoietic cell transplantation, outcome, t(8;16)(p11;p13)/MYST3-CREBBP, whole-genome sequencing,
 - MeSH
 - abnormální karyotyp MeSH
 - akutní myeloidní leukemie epidemiologie genetika terapie MeSH
 - analýza přežití MeSH
 - dospělí MeSH
 - fúzní onkogenní proteiny genetika MeSH
 - indukce remise MeSH
 - kombinovaná terapie MeSH
 - konsolidační chemoterapie MeSH
 - lidé středního věku MeSH
 - lidé MeSH
 - lidské chromozomy, pár 16 ultrastruktura MeSH
 - lidské chromozomy, pár 8 ultrastruktura MeSH
 - mezinárodní spolupráce MeSH
 - mladiství MeSH
 - mutace MeSH
 - myelodysplastické syndromy epidemiologie MeSH
 - následné studie MeSH
 - přežití bez známek nemoci MeSH
 - progrese nemoci MeSH
 - protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
 - sekundární malignity chemicky indukované epidemiologie MeSH
 - sekvenování celého genomu MeSH
 - senioři MeSH
 - translokace genetická * MeSH
 - transplantace hematopoetických kmenových buněk MeSH
 - Check Tag
 - dospělí MeSH
 - lidé středního věku MeSH
 - lidé MeSH
 - mladiství MeSH
 - mužské pohlaví MeSH
 - senioři MeSH
 - ženské pohlaví MeSH
 - Publikační typ
 - časopisecké články MeSH
 - multicentrická studie MeSH
 - práce podpořená grantem MeSH
 - Research Support, N.I.H., Extramural MeSH
 - Názvy látek
 - fúzní onkogenní proteiny MeSH
 
We conducted a large international nested case-control study including 1881 patients with Philadelphia-negative myeloproliferative neoplasms (MPN). Cases (n = 647) were patients with second cancer (SC: carcinoma, non-melanoma skin cancer, hematological second cancer, and melanoma) and controls (n = 1234) were patients without SC, matched with cases for sex, age at MPN diagnosis, date of MPN diagnosis, and MPN disease duration. The aim was to evaluate the risk of SC after exposure to cytoreductive drugs. Patients exposed to hydroxyurea (HU) (median: 3 years) had a risk of SC similar to unexposed patients (OR = 1.06, 95% CI 0.82-1.38). In contrast, in cancer-specific stratified multivariable analysis, HU had two-fold higher risk of non-melanoma (NM) skin cancer (OR = 2.28, 95% CI 1.15-4.51). A significantly higher risk of NM-skin cancer was also documented for pipobroman (OR = 3.74, 95% CI 1.00-14.01), ruxolitinib (OR = 3.87, 95% CI 1.18-12.75), and for drug combination (OR = 3.47, 95% CI 1.55-7.75). These three drugs did not show excess risk of carcinoma and hematological second cancer compared with unexposed patients. Exposure to interferon, busulfan, and anagrelide did not increase the risk. In summary, while it is reassuring that no excess of carcinoma was documented, a careful dermatologic active surveillance before and during the course of treatments is recommended.
- MeSH
 - esenciální trombocytemie farmakoterapie genetika MeSH
 - filadelfský chromozom * MeSH
 - hydroxymočovina škodlivé účinky MeSH
 - lidé MeSH
 - nitrily MeSH
 - pipobroman škodlivé účinky MeSH
 - polycythaemia vera farmakoterapie genetika MeSH
 - primární myelofibróza farmakoterapie MeSH
 - protinádorové látky škodlivé účinky MeSH
 - pyrazoly škodlivé účinky MeSH
 - pyrimidiny MeSH
 - sekundární malignity chemicky indukované MeSH
 - studie případů a kontrol MeSH
 - Check Tag
 - lidé MeSH
 - Publikační typ
 - časopisecké články MeSH
 - multicentrická studie MeSH
 - práce podpořená grantem MeSH
 - Názvy látek
 - hydroxymočovina MeSH
 - nitrily MeSH
 - pipobroman MeSH
 - protinádorové látky MeSH
 - pyrazoly MeSH
 - pyrimidiny MeSH
 - ruxolitinib MeSH Prohlížeč
 
BACKGROUND: Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence of second primary malignancies in patients with and without lenalidomide exposure. METHODS: We identified relevant studies through a search of PubMed and abstracts from the American Society of Clinical Oncology, American Society of Hematology, and the International Myeloma Workshop. Randomised, controlled, phase 3 trials that recruited patients with newly diagnosed multiple myeloma between Jan 1, 2000, and Dec 15, 2012, and in which at least one group received lenalidomide were eligible for inclusion. We obtained individual patient data (age, sex, date of diagnosis, allocated treatment and received treatment, duration of treatment and cause of discontinuation, maintenance treatment, date of first relapse, date of second primary malignancy diagnosis, type of second primary malignancy, date of death or last contact, and cause of death) by direct collaboration with the principal investigators of eligible trials. Primary outcomes of interest were cumulative incidence of all second primary malignancies, solid second primary malignancies, and haematological second primary malignancies, and were analysed by a one-step meta-analysis. FINDINGS: We found nine eligible trials, of which seven had available data for 3254 patients. 3218 of these patients received treatment (2620 had received lenalidomide and 598 had not), and were included in our analyses. Cumulative incidences of all second primary malignancies at 5 years were 6·9% (95% CI 5·3-8·5) in patients who received lenalidomide and 4·8% (2·0-7·6) in those who did not (hazard ratio [HR] 1·55 [95% CI 1·03-2·34]; p=0·037). Cumulative 5-year incidences of solid second primary malignancies were 3·8% (95% CI 2·7-4·9) in patients who received lenalidomide and 3·4% (1·6-5·2) in those that did not (HR 1·1 [95% CI 0·62-2·00]; p=0·72), and of haematological second primary malignancies were 3·1% (95% CI 1·9-4·3) and 1·4% (0·0-3·6), respectively (HR 3·8 [95% CI 1·15-12·62]; p=0·029). Exposure to lenalidomide plus oral melphalan significantly increased haematological second primary malignancy risk versus melphalan alone (HR 4·86 [95% CI 2·79-8·46]; p<0·0001). Exposure to lenalidomide plus cyclophosphamide (HR 1·26 [95% CI 0·30-5·38]; p=0·75) or lenalidomide plus dexamethasone (HR 0·86 [95% CI 0·33-2·24]; p=0·76) did not increase haematological second primary malignancy risk versus melphalan alone. INTERPRETATION: Patients with newly diagnosed myeloma who received lenalidomide had an increased risk of developing haematological second primary malignancies, driven mainly by treatment strategies that included a combination of lenalidomide and oral melphalan. These results suggest that alternatives, such as cyclophosphamide or alkylating-free combinations, should be considered instead of oral melphalan in combination with lenalidomide for myeloma. FUNDING: Celgene Corporation.
- MeSH
 - inhibitory angiogeneze škodlivé účinky MeSH
 - lenalidomid MeSH
 - lidé MeSH
 - melfalan škodlivé účinky MeSH
 - mnohočetný myelom farmakoterapie MeSH
 - sekundární malignity chemicky indukované MeSH
 - thalidomid škodlivé účinky analogy a deriváty MeSH
 - Check Tag
 - lidé MeSH
 - Publikační typ
 - časopisecké články MeSH
 - metaanalýza MeSH
 - práce podpořená grantem MeSH
 - Názvy látek
 - inhibitory angiogeneze MeSH
 - lenalidomid MeSH
 - melfalan MeSH
 - thalidomid MeSH
 
Data on secondary acute lymphoblastic leukaemia (sALL) following ALL treatment are very rare. However, the incidence might be underestimated as sALLs without a significant lineage shift might automatically be diagnosed as relapses. Examination of immunoglobulin and T-cell receptor gene rearrangements brought a new tool that can help in discrimination between relapse and sALL. We focused on the recurrences of childhood ALL to discover the real frequency of the sALL after ALL treatment. We compared clonal markers in matched presentation and recurrence samples of 366 patients treated according to the Berlin-Frankfurt-Munster (BFM)-based protocols. We found two cases of sALL and another three, where the recurrence is suspicious of being sALL rather than relapse. Our proposal for the 'secondary ALL after ALL' diagnostic criteria is as follows: (A) No clonal relationship between diagnosis and recurrence; (B) significant immunophenotypic shift--significant cytogenetic shift--gain/loss of a fusion gene. For the sALL (A) plus at least one (B) criterion should be fulfilled. With these criteria, the estimated frequency of the sALL after ALL is according to our data 0.5-1.5% of ALL recurrences on BFM-based protocols. Finally, we propose a treatment strategy for the patients with secondary disease.
- MeSH
 - akutní lymfatická leukemie chemicky indukované diagnóza farmakoterapie MeSH
 - diagnostické techniky molekulární metody MeSH
 - diferenciální diagnóza MeSH
 - genová přestavba T-lymfocytů MeSH
 - geny pro imunoglobuliny MeSH
 - imunofenotypizace MeSH
 - incidence MeSH
 - lidé MeSH
 - předškolní dítě MeSH
 - protinádorové látky škodlivé účinky MeSH
 - recidiva MeSH
 - sekundární malignity chemicky indukované diagnóza MeSH
 - Check Tag
 - lidé MeSH
 - mužské pohlaví MeSH
 - předškolní dítě MeSH
 - ženské pohlaví MeSH
 - Publikační typ
 - časopisecké články MeSH
 - práce podpořená grantem MeSH
 - Názvy látek
 - protinádorové látky MeSH
 
- MeSH
 - adenomyom chemicky indukované MeSH
 - hormonální protinádorové látky škodlivé účinky MeSH
 - lidé středního věku MeSH
 - lidé MeSH
 - nádory dělohy chemicky indukované MeSH
 - nádory prsu farmakoterapie MeSH
 - sekundární malignity chemicky indukované MeSH
 - tamoxifen škodlivé účinky MeSH
 - Check Tag
 - lidé středního věku MeSH
 - lidé MeSH
 - ženské pohlaví MeSH
 - Publikační typ
 - časopisecké články MeSH
 - kazuistiky MeSH
 - Názvy látek
 - hormonální protinádorové látky MeSH
 - tamoxifen MeSH